TXMD
NASDAQ · Pharmaceuticals
Therapeuticsmd Inc
$2.14
+0.04 (+1.90%)
Financial Highlights (FY 2026)
Revenue
3.01M
Net Income
-566,858
Gross Margin
100.0%
Profit Margin
-18.8%
Rev Growth
-64.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 47.0% | 47.0% |
| Operating Margin | -145.3% | -130.7% | 33.6% | 32.8% |
| Profit Margin | -18.8% | -17.9% | 26.2% | 22.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.01M | 8.58M | 4.86M | 6.01M |
| Gross Profit | 3.01M | 8.58M | 2.28M | 2.83M |
| Operating Income | -4,371,782 | -11,212,891 | 1.63M | 1.97M |
| Net Income | -566,858 | -1,453,896 | 1.27M | 1.34M |
| Gross Margin | 100.0% | 100.0% | 47.0% | 47.0% |
| Operating Margin | -145.3% | -130.7% | 33.6% | 32.8% |
| Profit Margin | -18.8% | -17.9% | 26.2% | 22.4% |
| Rev Growth | -64.9% | -64.9% | +8.5% | +15.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 6.73M | 8.04M |
| Total Equity | — | — | 11.85M | 11.59M |
| D/E Ratio | — | — | 0.57 | 0.69 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -3,989,899 | -10,801,949 | 2.17M | 2.73M |
| Free Cash Flow | — | — | 1.08M | 1.44M |